Dulaglutide-based therapy may potentiate improved glycemic variability (GV) in patients with type 2 diabetes (T2D) owing to their several pancreatic and extra-pancreatic effects. This study assessed the effects of dulaglutide on GV using continuous glucose monitoring system (CGMS) in patients with T2D. Patients (N = 27) from a CGMS specialty center in India received dulaglutide as add-on to oral antidiabetics (OADs) with or without insulin and were subsequently monitored for continuous glucose data using CGMS (FreeStyle Libre Pro) for ≤15 days considering 70-140 mg/dL as target. CGMS data revealed a significant reduction (P<.05) in overall within-patient mean CGM glucose on Day 5 relative to Day 1 which further reduced at Day 15 (Figure), warranting titration of doses of OADs and/or insulin. Interestingly, the coefficient of variation for overall within-patient mean glucose on Day 15 (21.99%) was less compared to Day 1 (31.56%). Through Day 1 to Day 15, overall within-patient mean % time of glucose in target significantly (P<.05) increased (25.19% to 66.42%) along with reduced mean % time above target (68.96% to 17.42%). A non-significant increase in overall mean % time below target (5.86% to 16.16%) was observed with no events of severe hypoglycemia. Dulaglutide improved GV and is well tolerated in patients with T2D.


S.A. Patange: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.